ES2149230T3 - Procedimiento para la esterilizacion de una composicion farmaceutica que contiene albumina serica humana recombinante. - Google Patents

Procedimiento para la esterilizacion de una composicion farmaceutica que contiene albumina serica humana recombinante.

Info

Publication number
ES2149230T3
ES2149230T3 ES94116937T ES94116937T ES2149230T3 ES 2149230 T3 ES2149230 T3 ES 2149230T3 ES 94116937 T ES94116937 T ES 94116937T ES 94116937 T ES94116937 T ES 94116937T ES 2149230 T3 ES2149230 T3 ES 2149230T3
Authority
ES
Spain
Prior art keywords
recombinant human
rhsa
sterilization
albumine
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94116937T
Other languages
English (en)
Inventor
Tomoshi The Green Cross C Ohya
Toyoo The Green Cross Cor Ohda
Shinobu The Green Cross Kuwae
Kenji The Green Cros Tomomitsu
Kaoru The Green Cros Kobayashi
Takao The Green Cross C Ohmura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Welfide Corp
Original Assignee
Welfide Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17468634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2149230(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Welfide Corp filed Critical Welfide Corp
Application granted granted Critical
Publication of ES2149230T3 publication Critical patent/ES2149230T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UNA PREPARACION FARMACEUTICA DE ALBUMINA DE SUERO HUMANO RECOMBINANTE (RHSA) ES ESTERILIZADA AL SOMETER UNA PREPARACION FARMACEUTICA O RHSA OBTENIDA POR TECNICAS DE MANIPULACION DE GENES EMPAQUETADOS EN UN CONTENEDOR CON UNA UNIDAD DE ADMINISTRACION PARA TRATAMIENTO DE CALOR ENTRE 50 Y 80 C DURANTE 30 MINUTOS O MAS. POR EL METODO DESCRITO, EL RHSA QUE TIENE ELEVADA SEGURIDAD PUEDE ESTAR PROVISTO DESDE QUE LOS MICROORGANISMOS CONTAMINADOS EN LAS PREPARACIONES FARMACEUTICAS RHSA SE EXTINGUEN COMO UN RESULTADO DEL METODO DE ESTERILIZACION DE LA PRESENTE INVENCION.
ES94116937T 1993-10-27 1994-10-26 Procedimiento para la esterilizacion de una composicion farmaceutica que contiene albumina serica humana recombinante. Expired - Lifetime ES2149230T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5269168A JPH07126182A (ja) 1993-10-27 1993-10-27 組換えヒト血清アルブミン製剤の滅菌方法

Publications (1)

Publication Number Publication Date
ES2149230T3 true ES2149230T3 (es) 2000-11-01

Family

ID=17468634

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94116937T Expired - Lifetime ES2149230T3 (es) 1993-10-27 1994-10-26 Procedimiento para la esterilizacion de una composicion farmaceutica que contiene albumina serica humana recombinante.

Country Status (8)

Country Link
US (1) US5691451A (es)
EP (1) EP0650736B1 (es)
JP (1) JPH07126182A (es)
KR (1) KR100371045B1 (es)
CA (1) CA2134535C (es)
DE (1) DE69425033T2 (es)
DK (1) DK0650736T3 (es)
ES (1) ES2149230T3 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0770676A3 (en) * 1995-10-23 1999-05-19 Ajinomoto Co., Ltd. Method for treating fermentation broth
US6197936B1 (en) 1998-10-21 2001-03-06 Nissho Corporation Method for producing a plastic vessel containing an albumin preparation
DE19907257A1 (de) * 1999-02-21 2000-09-14 Bernd Horst Meier Mittel zur Steuerung der Diffusion von Injektionslösungen
US6493867B1 (en) 2000-08-08 2002-12-10 Ball Semiconductor, Inc. Digital photolithography system for making smooth diagonal components
DE10040707A1 (de) * 2000-08-17 2002-03-14 Braun Melsungen Ag Kolloidale Pharmakomodulation injizierter Arzneimittel
JP4798833B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
JP4798832B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
US6730286B2 (en) * 2001-02-28 2004-05-04 Bracco Diagnostics, Inc. Manufacturing process to control particle size
KR101146946B1 (ko) 2003-04-09 2012-05-22 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 알부민 제제의 제조 방법
DE602005013912D1 (de) 2004-01-20 2009-05-28 Chemo Sero Therapeut Res Inst Verfahren zur herstellung von humanserumalbumin durch wärmebehandlung in gegenwart von zweiwertigem kation
EP2471557A1 (en) * 2010-12-27 2012-07-04 Università degli Studi di Genova A conjugate of human albumin and 2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid useful for the localization of radionuclides for diagnostic and therapeutic purposes
CN103923211A (zh) * 2014-05-08 2014-07-16 齐智 一种医药级重组人血清白蛋白的纯化方法
ES2524516B1 (es) * 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
ES2780367T3 (es) * 2015-01-01 2020-08-25 Shilpa Medicare Ltd Nuevo método de purificación eficiente de albumina sérica humana
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue
JP3554796B2 (ja) * 1988-10-31 2004-08-18 三菱ウェルファーマ株式会社 アルブミン製剤及びその製造方法
JPH0768137B2 (ja) * 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
JPH0671434B2 (ja) * 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
JP3230091B2 (ja) * 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
JPH0671432B2 (ja) * 1991-03-20 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
JPH07102147B2 (ja) * 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法

Also Published As

Publication number Publication date
KR950010898A (ko) 1995-05-15
DE69425033T2 (de) 2001-03-08
EP0650736B1 (en) 2000-06-28
KR100371045B1 (ko) 2003-03-19
JPH07126182A (ja) 1995-05-16
DK0650736T3 (da) 2000-08-28
CA2134535A1 (en) 1995-04-28
CA2134535C (en) 2004-06-08
EP0650736A1 (en) 1995-05-03
US5691451A (en) 1997-11-25
DE69425033D1 (de) 2000-08-03

Similar Documents

Publication Publication Date Title
ES2149230T3 (es) Procedimiento para la esterilizacion de una composicion farmaceutica que contiene albumina serica humana recombinante.
MX7603E (es) Procedimiento para preparar una composicion neutralizante de peroxido de hidrogeno
ATE193418T1 (de) Dekontaminierung von plättchen mit 8- methoxypsoralen
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
ES2098029T3 (es) Vacunas de hepatitis que contienen monofosforil lipido a 3-o-desacilado.
MX9606732A (es) Compuestos terapeuticos.
ES2057191T5 (es) Metodo de produccion para una composicion que contiene proteinas.
ATE97316T1 (de) Kosmetisches mittel und zusammensetzung zur behandlung der haut.
DE3683333D1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
ES2163795T3 (es) Composicion farmaceutica contra los tumores e infecciones por papilomavirus.
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
BR9914530A (pt) Aplicação de composição oftálmica compreendendo vitamina a e vitamina e
DK0951553T3 (da) Adenovirus-E4-proteiner til induktion af celledød
SE8101833L (sv) Stabil bensoylperoxidkomposition
CO4520283A1 (es) Agentes antivirales
ES2191083T3 (es) Composicion para limpiar y/o desinfectar instrumentos para uso medico.
ES2058100T3 (es) Vacuna combinada.
Mirhashemi et al. Effect of enamel surface pretreatment with different laser types and antioxidizing agents office-bleaching on the shear bond strength of orthodontic brackets
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
Kornhall et al. Ambulatory inguinal hernia repair compared with short-stay surgery
ES2037109T3 (es) Procedimiento para preparar productos farmaceuticos para el tratamiento topico de eflorescencias por virus del herpes.
ES2128322T3 (es) Peptidos que bloquean las infecciones debidas al virus de la inmunodeficiencia humana y procedimientos de utilizacion de estos peptidos.
FI943295A (fi) Piliostigma thonningii -uutteet, niiden käyttö ja niitä sisältävät formuloinnit
Nemtsev LASERS USED II TREATMENT OF BURNS
SU1565027A1 (ru) Инактиватор вируса западного нила

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 650736

Country of ref document: ES